The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Is The Market Size Of The Cancer Biomarker Market In 2026 And What Value Is Projected For 2030?
The cancer biomarker market has experienced substantial expansion in recent years. It is forecast to increase from $25.09 billion in 2025 to $29.07 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 15.9%. The growth witnessed during past periods stemmed from factors such as the escalating global prevalence of cancer, breakthroughs in molecular biology research, an increase in oncology research funding, the widespread adoption of diagnostics based on biomarkers, and enhancements in imaging and assay technologies.
The cancer biomarker market is anticipated to experience significant expansion in the coming years. It will grow to $52.63 billion in 2030 at a compound annual growth rate (CAGR) of 16.0%. This projected growth is fueled by a rising need for tailored oncology therapies, increased funding in precision medicine, the proliferation of biomarker-guided drug discovery, wider adoption of AI-powered biomarker analysis, and an intensified emphasis on detecting cancer at early stages. Key developments expected during this timeframe encompass the expanded application of genetic and protein biomarkers, a surge in the embrace of companion diagnostics, deeper incorporation of omics technologies, broader utilization of liquid biopsy techniques, and a sharpened emphasis on identifying cancer early.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8492&type=smp
Which Growth Drivers Are Contributing To The Progress Of The Cancer Biomarker Market?
The increasing occurrence of cancer is a key factor driving the expansion of the cancer biomarker market. The cancer incidence rate defines the number of new cancers of a specific site or type that appear in a population during a particular year, expressed as cancers per 100,000 individuals at risk. This growing incidence of cancer leads to the widespread adoption of cancer biomarkers, which are instrumental in evaluating disease risk, screening for hidden primary tumors, distinguishing between benign and malignant indicators, or differentiating various forms of malignancy. Cancer biomarkers are crucial for the early detection, diagnosis, and ongoing monitoring of cancer by indicating the disease’s presence or progression, thereby enabling personalized treatments and improving patient outcomes. For instance, a report published in May 2024 by the International Agency for Research on Cancer (IARC), a France-based cancer research organization, noted that in 2022, approximately 20 million new cancer cases were reported, resulting in 9.7 million deaths. Projections suggest that by 2050, new cancer cases will exceed 35 million, representing a 77% increase compared to 2022. Consequently, the increasing occurrence of cancer packaging is anticipated to fuel the expansion of the cancer biomarker market in the upcoming years.
What Are The Key Segments Of The Cancer Biomarker Market?
The cancer biomarker market covered in this report is segmented –
1) By Biomarker Type: Protein Biomarkers, Genetic Biomarkers, Other Biomarker Types
2) By Profiling Technologies: Omics Technologies, Immunoassay, Bioinformatics, Cytogenetics
3) By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Thyroid Cancer, Kidney Cancer, Other Cancers
4) By Application: Diagnostics, Research And Development, Prognostics, Risk Assessment, Other Applications
Subsegments:
1) By Protein Biomarkers: Tumor-Specific Antigens, Circulating Tumor Protein
2) By Genetic Biomarkers: DNA Mutations, RNA Expression Profiles
3) By Other Biomarker Types: Epigenetic Biomarkers, Metabolomic Biomarkers
What Key Trends Are Influencing The Development Of The Cancer Biomarker Market?
Major companies operating in the cancer biomarker market are concentrating on developing innovative solutions, such as AI-driven cancer biomarkers, to enhance diagnostic precision and personalize treatment plans for individuals. AI-powered cancer biomarkers refer to biological indicators of cancer identified and analyzed using artificial intelligence technologies. For instance, in September 2023, Ibex Medical Analytics, a US-based Ibex Medical Analytics, launched Galen Breast HER2, an AI-powered solution designed to improve the accuracy and reproducibility of HER2 scoring in breast cancer patients. This innovative platform assists pathologists by automatically detecting invasive tumor areas and quantifying HER2 expression based on the 2018 ASCO/CAP guidelines. The Galen Breast HER2 system utilizes a novel computational pipeline to analyze immunohistochemistry (IHC)-stained slides, providing detailed visualizations of staining patterns and enabling pathologists to make informed treatment decisions.
Who Are The Leading Companies Operating In The Cancer Biomarker Market?
Major companies operating in the cancer biomarker market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., QIAGEN NV, Illumina Inc., Bio-Rad Laboratories Inc., Abbott Laboratories, bioMérieux SA, Becton Dickinson and Company, Merck & Co. Inc., Bristol-Myers Squibb Company, PerkinElmer Inc., Siemens AG, Exact Sciences Corporation, Novartis AG, Agilent Technologies Inc., Hologic Inc., Myriad Genetics Inc., Foundation Medicine Inc., Guardant Health Inc., Natera Inc., Sysmex Corporation, Biocartis Group NV, NanoString Technologies Inc., Veracyte Inc., Epic Sciences Inc., Cynvenio Biosystems Inc., Genomic Health Inc., Oncocyte Corporation, Exosome Diagnostics Inc., Grail Inc.
Read the full cancer biomarker market report here:
https://www.thebusinessresearchcompany.com/report/cancer-biomarker-global-market-report
What Are The Leading Geographic Regions In The Cancer Biomarker Market?
North America was the largest region in the cancer biomaker market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer biomarker market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Cancer Biomarker Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=8492&type=smp
Browse Through More Reports Similar to the Global Cancer Biomarker Market 2026, By The Business Research Company
Calcium Peroxide Market Report 2026
https://www.thebusinessresearchcompany.com/report/calcium-peroxide-global-market-report
Calcium Channel Blocker Market Report 2026
https://www.thebusinessresearchcompany.com/report/calcium-channel-blocker-global-market-report
Calcium Nitrate Market Report 2026
https://www.thebusinessresearchcompany.com/report/calcium-nitrate-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model